Status:
UNKNOWN
Brain Network Activation in Patients With Movement Disorders
Lead Sponsor:
Sheba Medical Center
Conditions:
Parkinson Disease
Essential Tremor
Eligibility:
All Genders
18-85 years
Brief Summary
The diagnosis and management of movement disorders, such as Parkinson's disease (PD), parkinson-plus syndromes (PPS), dystonia, essential tremor (ET), normal pressure hydrocephalus (NPH) and others is...
Detailed Description
Objective: The primary aim of the current project is to assess the utility of the BNA as a quantitative, objective, neurophysiological marker for diagnosis and monitoring of the above most common MDi ...
Eligibility Criteria
Inclusion
- For PD: Idiopathic PD patients (according to the UK PD Society brain bank clinical diagnostic criteria (bradykinesia plus at least one other cardinal feature of PD, no atypical features or secondary cause).
- For ET: bilateral, largely symmetrical postural or kinetic tremor involving hand and forearms that is visible and persistent. Additional or isolated tremor of the head may occur but in the absence of abnormal posturing.
- For Parkinson plus syndrome: multiple system atrophy (MSA), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and dementia with Lewy bodies (DLB).
- For NPH: patients exhibiting some or all components of the clinical triad consisting of gait disturbance, urinary control disturbance and cognitive impairment as well as proof of enlarged ventricular system or hydrocephalus by cranial CT or MRI scans.
- For Dystonia: patients exhibiting a movement disorder syndrome in which sustained or repetitive muscle contractions result in twisting and repetitive movements or abnormal fixed postures. The movements may resemble a tremor. Patients included will be those with either idiopathic, toxic or hereditary mechanism.
- For Cerebellar ataxia: patients exhibiting impairment of coordination and balance as part of an ataxic cerebellar syndrome which is caused by degeneration of the cerebellum and its afferent and efferent connections due to various etiologies, such as genetic or sporadic neurodegenerative processes or others.
Exclusion
- In the investigator's opinion, any unstable or clinically significant condition that would impair the participants' ability to comply with study requirements.
- Patients with significant psychiatric symptoms or history or treatment with neuroleptics.
- MMSE \<10
- Currently with lice or open wounds on scalp.
- Significant sensory deficits, e.g., deafness or blindness
- Current drug abuse or alcoholism.
Key Trial Info
Start Date :
March 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 15 2022
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT03269201
Start Date
March 1 2019
End Date
September 15 2022
Last Update
March 19 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Movement Disorders Clinic, Sheba Medical Center
Ramat Gan, Israel, 52621